Spero Therapeutics, Inc. (NASDAQ:SPRO) will hold its 3Q20 earnings conference call with the financial community on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at sperotherapeutics.com
Earnings Expectation
Spero Therapeutics, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SPRO is expected to report 3Q20 loss of $ 0.87 per share from revenue of $ 3.20 million.
For the full year, analysts anticipate top line of $ 10.76 million, while looking forward to loss of $ 3.55 per share bottom line.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc.
